相似文献
1
Estimating the sensitivity of a screening test.
J Epidemiol Community Health. 1985 Dec;39(4):364-6. doi: 10.1136/jech.39.4.364.
2
Estimating Cancer Screening Sensitivity and Specificity Using Healthcare Utilization Data: Defining the Accuracy Assessment Interval.
Cancer Epidemiol Biomarkers Prev. 2022 Aug 2;31(8):1517-1520. doi: 10.1158/1055-9965.EPI-22-0232.
3
Prevalence threshold (ϕe) and the geometry of screening curves.
PLoS One. 2020 Oct 7;15(10):e0240215. doi: 10.1371/journal.pone.0240215. eCollection 2020.
4
Estimating lead time and sensitivity in a screening program without estimating the incidence in the screened group.
Biometrics. 1997 Mar;53(1):217-29.
5
Screening for disease: making evidence-based choices.
Clin J Oncol Nurs. 2006 Feb;10(1):73-6. doi: 10.1188/06.CJON.73-76.
6
Principles of cancer screening for clinicians.
Prim Care. 1992 Sep;19(3):513-33.
7
Estimating true burden of disease detected by screening tests of varying validity.
Indian J Public Health. 2001 Jan-Mar;45(1):14-9.
8
9
Development and verification of a model for estimating the screening utility in the detection of PCBs in transformer oil.
Anal Sci. 2014;30(3):413-8. doi: 10.2116/analsci.30.413.
10
Estimation of natural history parameters of breast cancer based on non-randomized organized screening data: subsidiary analysis of effects of inter-screening interval, sensitivity, and attendance rate on reduction of advanced cancer.
Breast Cancer Res Treat. 2010 Jul;122(2):553-66. doi: 10.1007/s10549-009-0701-x. Epub 2010 Jan 7.
引用本文的文献
1
Interval cancers in a population-based screening program for colorectal cancer with gender-specific cut-off levels for fecal immunochemical test.
J Med Screen. 2022 Sep;29(3):156-165. doi: 10.1177/09691413221085218. Epub 2022 Mar 8.
2
Modeling the mean time to interval cancer after negative results of periodic cancer screening.
Stat Med. 2021 Mar 15;40(6):1429-1439. doi: 10.1002/sim.8849. Epub 2020 Dec 13.
3
Overdiagnosis of gastric cancer by endoscopic screening.
World J Gastrointest Endosc. 2017 Feb 16;9(2):55-60. doi: 10.4253/wjge.v9.i2.55.
4
Clarifying the debate on population-based screening for breast cancer with mammography: A systematic review of randomized controlled trials on mammography with Bayesian meta-analysis and causal model.
Medicine (Baltimore). 2017 Jan;96(3):e5684. doi: 10.1097/MD.0000000000005684.
5
Benefits and harms of endoscopic screening for gastric cancer.
World J Gastroenterol. 2016 Jul 28;22(28):6385-92. doi: 10.3748/wjg.v22.i28.6385.
6
Estimation of overdiagnosis using short-term trends and lead time estimates uncontaminated by overdiagnosed cases: Results from the Norwegian Breast Screening Programme.
J Med Screen. 2016 Dec;23(4):192-202. doi: 10.1177/0969141315623980. Epub 2016 Mar 2.
7
Current issues and future perspectives of gastric cancer screening.
World J Gastroenterol. 2014 Oct 14;20(38):13767-74. doi: 10.3748/wjg.v20.i38.13767.
8
Guaiac faecal occult blood test performance at initial and repeat screens in the English Bowel Cancer Screening Programme.
Br J Cancer. 2014 Oct 28;111(9):1734-41. doi: 10.1038/bjc.2014.469. Epub 2014 Sep 2.
9
Performance measures in three rounds of the English bowel cancer screening pilot.
Gut. 2012 Jan;61(1):101-7. doi: 10.1136/gut.2010.236430. Epub 2011 May 10.
10
Comparison of a guaiac and an immunochemical faecal occult blood test for the detection of colonic lesions according to lesion type and location.
Br J Cancer. 2009 Apr 21;100(8):1230-5. doi: 10.1038/sj.bjc.6604996. Epub 2009 Mar 31.
本文引用的文献
1
Simplified models of screening for chronic disease: estimation procedures from mass screening programmes.
Biometrics. 1984 Mar;40(1):1-14.
2
Repeated screening for breast cancer.
J Epidemiol Community Health. 1984 Mar;38(1):54-7. doi: 10.1136/jech.38.1.54.
3
Estimation of the duration of a pre-clinical disease state using screening data.
Am J Epidemiol. 1983 Dec;118(6):865-86. doi: 10.1093/oxfordjournals.aje.a113705.
Zotero 插件